Saadoun Rakan, Risse Eva-Maria, Obermueller Theresa, Bittar Ranim, Aderhold Christoph
Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Centre Mannheim, Mannheim, DEU.
Faculty of Medicine Mannheim, Ruprecht Karls University Heidelberg, Mannheim, DEU.
Cureus. 2021 Feb 18;13(2):e13410. doi: 10.7759/cureus.13410.
The secondary manifestation of a marginal zone lymphoma (MZL), which is a less common type of B-cell non-Hodgkin's Lymphoma (NHL), in the larynx is a rarity. We report a case of the secondary involvement of the larynx following MZL in a 72-year-old woman who presented with the sensation of a foreign body in the throat and history of MZL. A fiberoptic laryngoscopy confirmed the presence of a mass in the supraglottic area. The initial clinical evaluation indicated that the mass was benign. Hence, it was removed surgically. However, the histopathological analysis confirmed the diagnosis of MZL. After a systemic evaluation, the patient was classified as stage IV A according to the Ann Arbor staging system for lymphomas. Treatment was initiated with Ibrutinib 520mg/d and Rituximab 375 mg/m every 28 days. When it comes to tumors of the head and neck, including NHL, the larynx should also be considered as a site for a possible secondary as well as primary involvement.
边缘区淋巴瘤(MZL)是一种不太常见的B细胞非霍奇金淋巴瘤(NHL),其在喉部的继发表现极为罕见。我们报告一例72岁女性患者,在患有边缘区淋巴瘤并出现咽喉部异物感后,喉部出现继发受累情况。纤维喉镜检查证实声门上区有肿物。初步临床评估显示该肿物为良性。因此,对其进行了手术切除。然而,组织病理学分析确诊为边缘区淋巴瘤。经过全面评估,根据淋巴瘤的Ann Arbor分期系统,该患者被分类为IV A期。治疗方案为起始使用依鲁替尼520mg/天,每28天使用利妥昔单抗375mg/m²。对于包括非霍奇金淋巴瘤在内的头颈部肿瘤,喉部也应被视为可能出现继发和原发受累的部位。